These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34145376)

  • 41. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy
    Denkert C; Untch M; Benz S; Schneeweiss A; Weber KE; Schmatloch S; Jackisch C; Sinn HP; Golovato J; Karn T; Marmé F; Link T; Budczies J; Nekljudova V; Schmitt WD; Stickeler E; Müller V; Jank P; Parulkar R; Heinmöller E; Sanborn JZ; Schem C; Sinn BV; Soon-Shiong P; van Mackelenbergh M; Fasching PA; Rabizadeh S; Loibl S
    Ann Oncol; 2021 Apr; 32(4):500-511. PubMed ID: 33418062
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
    Mutter RW; Riaz N; Ng CK; Delsite R; Piscuoglio S; Edelweiss M; Martelotto LG; Sakr RA; King TA; Giri DD; Drobnjak M; Brogi E; Bindra R; Bernheim G; Lim RS; Blecua P; Desrichard A; Higginson D; Towers R; Jiang R; Lee W; Weigelt B; Reis-Filho JS; Powell SN
    J Pathol; 2017 Jun; 242(2):165-177. PubMed ID: 28299801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
    Rabban JT; Chen LM; Devine WP
    Surg Pathol Clin; 2022 Jun; 15(2):219-234. PubMed ID: 35715159
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.
    Galland L; Roussot N; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Reda M; Albuisson J; Arnould L; Boidot R; Truntzer C; Ghiringhelli F; Ladoire S
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831640
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid.
    Roussel-Simonin C; Blanc-Durand F; Tang R; Vasseur D; Le Formal A; Chardin L; Yaniz E; Gouy S; Maulard A; Scherier S; Sanson C; Lacroix L; Cotteret S; Mauny L; Zaccarini F; Rouleau E; Leary A
    Mol Cancer; 2023 Nov; 22(1):178. PubMed ID: 37932736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).
    Rempel E; Kluck K; Beck S; Ourailidis I; Kazdal D; Neumann O; Volckmar AL; Kirchner M; Goldschmid H; Pfarr N; Weichert W; Hübschmann D; Fröhling S; Sutter C; Schaaf CP; Schirmacher P; Endris V; Stenzinger A; Budczies J
    NPJ Precis Oncol; 2022 Jun; 6(1):36. PubMed ID: 35681079
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration.
    Tsang ES; Csizmok V; Williamson LM; Pleasance E; Topham JT; Karasinska JM; Titmuss E; Schrader I; Yip S; Tessier-Cloutier B; Mungall K; Ng T; Sun S; Lim HJ; Loree JM; Laskin J; Marra MA; Jones SJM; Schaeffer DF; Renouf DJ
    NPJ Precis Oncol; 2023 Mar; 7(1):31. PubMed ID: 36964191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.
    Moretto R; Elliott A; Zhang J; Arai H; Germani MM; Conca V; Xiu J; Stafford P; Oberley M; Abraham J; Spetzler D; Rossini D; Antoniotti C; Marshall J; Shields A; Lopes G; Lonardi S; Pietrantonio F; Tomasello G; Passardi A; Tamburini E; Santini D; Aprile G; Masi G; Falcone A; Lenz HJ; Korn M; Cremolini C
    J Natl Cancer Inst; 2022 Feb; 114(2):271-279. PubMed ID: 34469533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.
    Ma J; Shah R; Bell AC; McDermott N; Pei X; Selenica P; Haseltine J; Delsite R; Khan AJ; Lok BH; Ellis MJ; Aft RF; Setton J; Reis-Filho JS; Riaz N; Powell SN
    Int J Radiat Oncol Biol Phys; 2024 Jul; ():. PubMed ID: 38997095
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
    Kadouri L; Rottenberg Y; Zick A; Hamburger T; Lipson D; Peretz T; Nechushtan H
    Lung Cancer; 2019 Nov; 137():48-51. PubMed ID: 31542568
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.
    Moore GM; Powell SN; Higginson DS; Khan AJ
    Breast Cancer Res Treat; 2022 Apr; 192(3):649-653. PubMed ID: 35092538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.
    Wang Y; Park JYP; Pacis A; Denroche RE; Jang GH; Zhang A; Cuggia A; Domecq C; Monlong J; Raitses-Gurevich M; Grant RC; Borgida A; Holter S; Stossel C; Bu S; Masoomian M; Lungu IM; Bartlett JMS; Wilson JM; Gao ZH; Riazalhosseini Y; Asselah J; Bouganim N; Cabrera T; Boucher LM; Valenti D; Biagi J; Greenwood CMT; Polak P; Foulkes WD; Golan T; O'Kane GM; Fischer SE; Knox JJ; Gallinger S; Zogopoulos G
    Clin Cancer Res; 2020 Oct; 26(20):5462-5476. PubMed ID: 32816949
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
    PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Homologous Recombination Deficiency Scar: Mutations and Beyond-Implications for Precision Oncology.
    van der Wiel AMA; Schuitmaker L; Cong Y; Theys J; Van Hoeck A; Vens C; Lambin P; Yaromina A; Dubois LJ
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer.
    Brown LC; Zhu J; Mauer E; Thiede SN; Macera L; Stein MM; Taxter T; Raghavan D; Burgess EF
    JCO Precis Oncol; 2023 Sep; 7():e2300378. PubMed ID: 38061006
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer.
    Jönsson JM; Bååth M; Björnheden I; Sahin ID; Måsbäck A; Hedenfalk I
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445465
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
    Lotan TL; Kaur HB; Salles DC; Murali S; Schaeffer EM; Lanchbury JS; Isaacs WB; Brown R; Richardson AL; Cussenot O; Cancel-Tassin G; Timms KM; Antonarakis ES
    Mod Pathol; 2021 Jun; 34(6):1185-1193. PubMed ID: 33462368
    [TBL] [